Integral Health Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Integral Health Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-234,830	Closed	-$2.28M	–	73
2022 Q2	$2.28M	Buy	234,830 +63,830	+37%	+$596K	0.47%	56
2022 Q1	$1.7M	Buy	171,000 +31,000	+22%	+$328K	0.44%	57
2021 Q4	$1.65M	Buy	+140,000	New	+$1.72M	0.46%	58
2021 Q1	–	Sell	-135,000	Closed	-$2.38M	–	82
2020 Q4	$2.38M	Buy	135,000 +15,000	+13%	+$263K	0.71%	43
2020 Q3	$1.84M	Buy	+120,000	New	+$2.25M	0.56%	60

Other funds holding KNSA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Integral Health Asset Management's KNSA Position: Q3 2022 in Review

Integral Health Asset Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2022, closing a stake of 234,830 shares — an estimated $2.28M sold.

Integral Health Asset Management first reported a position in KNSA in Q3 2020 and held it in 5 quarters. The position peaked at $2.38M in Q4 2020. 104 funds tracked by Wall St. Rank hold KNSA as of Q3 2022.

Integral Health Asset Management reported no remaining Kiniksa Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Integral Health Asset Management sold 234,830 Kiniksa Pharmaceuticals shares in Q3 2022, an estimated $2.28M.
Integral Health Asset Management first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 5 quarters.
Integral Health Asset Management's Kiniksa Pharmaceuticals position peaked at $2.38M in Q4 2020.
104 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2022.

Based on Integral Health Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.